Mark Ma, M.D., M.Sc.
About Mark Ma, M.D., M.Sc.
Educational Background of Mark Ma, M.D., M.Sc.
Mark Ma earned an M.D. and a master's degree in immunology from Furth Medical University in Beijing, China. His academic background in medical and immunological sciences laid the foundation for his expertise in bioanalytical research and biomarker development.
Professional Experience at Alexion Pharmaceuticals
Mark Ma previously served as the Executive Director of Bioanalytical and Biomarker Development at Alexion Pharmaceuticals, a subsidiary of AstraZeneca. During his tenure, he oversaw the development of bioanalytical methods and biomarker strategies, contributing to the company's drug development pipeline.
Role at Amgen Inc.
At Amgen Inc., Mark Ma was the Director of Bioanalytical Sciences. He provided essential bioanalytical and biomarker support for preclinical and clinical programs, aiding in the progression of preclinical drug development and ensuring the scientific rigor of Amgen's research initiatives.
Chair of AAPS Bioanalytical Community
Mark Ma currently serves as the chair of the American Association of Pharmaceutical Scientists (AAPS) Bioanalytical Community. In this role, he oversees the community’s activities and initiatives, facilitating collaboration and knowledge exchange among professionals in the field.
Leadership in AAPS Pharmacokinetic Assay Working Group
Since 2014, Mark Ma has led the pharmacokinetic assay working group under AAPS. His leadership in this capacity involves guiding the development and standardization of pharmacokinetic assays, which are crucial for drug development and therapeutic monitoring.